» Articles » PMID: 8398688

Tumourigenesis Associated with the P53 Tumour Suppressor Gene

Overview
Journal Br J Cancer
Specialty Oncology
Date 1993 Oct 1
PMID 8398688
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

The p53 gene is contained within 16-20 kb of cellular DNA located on the short arm of human chromosome 17 at position 17p13.1. This gene encodes a 393-amino-acid nuclear phosphoprotein involved in the regulation of cell proliferation. Current evidence suggests that loss of normal p53 function is associated with cell transformation in vitro and development of neoplasms in vivo. More than 50% of human malignancies of epithelial, mesenchymal, haematopoietic, lymphoid, and central nervous system origin analysed thus far, were shown to contain an altered p53 gene. The oncoproteins derived from several tumour viruses, including the SV40 large T antigen, the adenovirus E1B protein and papillomavirus E6 protein, as well as specific cellular gene products, e.g. murine double minute-2 (MDM2), were found to bind to the wild-type p53 protein and presumably lead to inactivation of this gene product. Therefore, the inactivation of p53 tumour suppressor gene is currently regarded as an almost universal step in the development of human cancers. The current data on p53-associated tumourigenesis are briefly discussed in this minireview.

Citing Articles

Effects of Tp53 Gene Mutations on the Survival of Non-Small Cell Lung Cancer (NSCLC); A Short Review.

Zhang C, Yang C, Shi Q Cancer Manag Res. 2025; 17():65-82.

PMID: 39830995 PMC: 11742633. DOI: 10.2147/CMAR.S495006.


Analysis of targeted somatic mutations in pleomorphic carcinoma of the lung using next-generation sequencing technique.

Manabe S, Kasajima R, Murakami S, Miyagi Y, Yokose T, Kondo T Thorac Cancer. 2020; 11(8):2262-2269.

PMID: 32578376 PMC: 7396383. DOI: 10.1111/1759-7714.13536.


Squamous Metaplasia Is Increased in the Bronchial Epithelium of Smokers with Chronic Obstructive Pulmonary Disease.

Rigden H, Alias A, Havelock T, ODonnell R, Djukanovic R, Davies D PLoS One. 2016; 11(5):e0156009.

PMID: 27228128 PMC: 4881906. DOI: 10.1371/journal.pone.0156009.


Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients.

Trino S, Iacobucci I, Erriquez D, Laurenzana I, De Luca L, Ferrari A Oncotarget. 2016; 7(11):12951-61.

PMID: 26887044 PMC: 4914334. DOI: 10.18632/oncotarget.7339.


Biology of colorectal cancer.

Arvelo F, Sojo F, Cotte C Ecancermedicalscience. 2015; 9:520.

PMID: 25932044 PMC: 4404039. DOI: 10.3332/ecancer.2015.520.


References
1.
Tan T, Wallis J, Levine A . Identification of the p53 protein domain involved in formation of the simian virus 40 large T-antigen-p53 protein complex. J Virol. 1986; 59(3):574-83. PMC: 253211. DOI: 10.1128/JVI.59.3.574-583.1986. View

2.
Bishop J . The molecular genetics of cancer. Science. 1987; 235(4786):305-11. DOI: 10.1126/science.3541204. View

3.
Schmieg F, Simmons D . Characterization of the in vitro interaction between SV40 T antigen and p53: mapping the p53 binding site. Virology. 1988; 164(1):132-40. DOI: 10.1016/0042-6822(88)90628-9. View

4.
Rovinski B, Benchimol S . Immortalization of rat embryo fibroblasts by the cellular p53 oncogene. Oncogene. 1988; 2(5):445-52. View

5.
Whyte P, Buchkovich K, Horowitz J, Friend S, Raybuck M, Weinberg R . Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature. 1988; 334(6178):124-9. DOI: 10.1038/334124a0. View